Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar(Mayo Clinic in Arizona), Jean‐Luc Harousseau(Centre Hospitalier Universitaire de Nantes), Brian G.M. Durie(Cedars-Sinai Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Robert A. Kyle(Mayo Clinic in Arizona), Joan Bladé(Hospital Clínic de Barcelona), Paul G. Richardson(Dana-Farber Cancer Institute), Robert Z. Orlowski(The University of Texas MD Anderson Cancer Center), David S. Siegel(Hackensack University Medical Center), Sundar Jagannath(Icahn School of Medicine at Mount Sinai), Thierry Façon(Centre Hospitalier Universitaire de Lille), Hervé Avet‐Loiseau(Centre Hospitalier Universitaire de Nantes), Sagar Lonial(Emory Healthcare), Antonio Palumbo(University of Turin), Jeffrey A. Zonder(Wayne State University), Heinz Ludwig(Wilhelminen Hospital), David H. Vesole(Hackensack University Medical Center), Orhan Sezer(Universität Hamburg), Nikhil C. Munshi(VA Boston Healthcare System), Jesús F. San Miguel(Centro de Investigación del Cáncer), on behalf of the International Myeloma Workshop Consensus Panel 1
Cited by 1,030Open Access
Abstract
It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript.
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Paul G. Richardson, Bart Barlogie, James R. Berenson et al.|New England Journal of Medicine|2003|2.6k
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al.|New England Journal of Medicine|2005|2.5k
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva et al.|New England Journal of Medicine|2008|1.9k